• Britney A Helling and Ivana V Yang.
• aDepartment of Medicine, University of Colorado School of Medicine bDepartment of Epidemiology, Colorado School of Public Health, Aurora cCenter for Genes, Environment and Health, National Jewish Health, Denver, Colorado, USA.
• Curr Opin Pulm Med. 2015 Sep 1; 21 (5): 454-62.

Purpose Of ReviewIdiopathic pulmonary fibrosis (IPF) is a fatal disease with limited treatment options and extensive gene expression changes identified in the lung parenchyma. Multiple lines of evidence suggest that epigenetic factors contribute to dysregulation of gene expression in IPF lung. Most importantly, risk factors that predispose to IPF - age, sex, cigarette smoke, and genetic variants - all influence epigenetic marks. This review summarizes recent findings of association of DNA methylation and histone modifications with the presence of disease and fibroproliferation.Recent FindingsIn addition to targeted studies focused on specific gene loci, genome-wide profiles of DNA methylation demonstrate widespread DNA methylation changes in IPF lung tissue and a substantial effect of these methylation changes on gene expression. Genetic loci that have been recently associated with IPF also contain differentially methylated regions, suggesting that genetic and epigenetic factors act in concert to dysregulate gene expression in IPF lung.SummaryAlthough we are in very early stages of understanding the role of epigenetics in IPF, the potential for the use of epigenetic marks as biomarkers and therapeutic targets is high and discoveries made in this field will likely bring us closer to better prognosticating and treating this fatal disease.

10 keywords...

hide…